Nektar Shares Rise On Morgan Joseph Analyst View
- Loading Comments...
NEW YORK (AP) — Shares of Nektar Therapeutics jumped Friday after a Morgan Joseph analyst reaffirmed a positive outlook for the developer of drug-delivery technology on its various partnerships.
The stock rose 37 cents, or 6.6 percent, to $6 in midday trading. Shares have traded between $2.45 and $7.13 over the last 52 weeks.
Morgan Joseph analyst Shiv Kapoor reaffirmed a "Buy" rating and boosted his price target to $9 from $7, citing the company's momentum in collaborations. Nektar's technology platform is used to enhance the performance of treatments. Its partner UCB received approval in May for Cimzia as a rheumatoid arthritis drug, which helps position Nektar in a market that has billions in revenue. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,388.90 | 1,105.98 | 2,194.35 | 34.83 |
Oil *
77.74
|
|
UP
22.75
|
UP
6.06
|
UP
21.21
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.75
|
|
+0.22%
|
+0.55%
|
+0.98%
|
+3.05%
|
Data delayed 20 minutes |
Connect with TheStreet